Apogee Therapeutics (APGE) is set to present new 52-week results from Part A of its Phase 2 APEX trial evaluating Zumilokibart in patients with moderate-to-severe atopic dermatitis. The data will be reported today, March 23, 2026, during a company webcast scheduled for 8:00 am ET, marking an important milestone for its lead anti-IL-13 antibody program.
Zumilokibart (APG777) is engineered for extended half-life and infrequent dosing, with the potential to offer every three- or six-months administration- an approach Apogee believes could set a new standard in the atopic dermatitis market.
The APEX trial consists of two complementary components. Part A is a 52-week maintenance phase designed to evaluate long-term safety, durability of response, and the ability to maintain skin clearance over a full year of treatment. Today's readout is expected to clarify whether Zumilokibart can deliver sustained benefit with its extended-interval dosing strategy.
Part B, by contrast, is a 16-week induction phase comparing low, medium, and high doses of the antibody against placebo. Enrollment for Part B has already been completed, and the company expects to report the 16-week results in the second quarter of 2026. These data will help refine dose selection as Apogee prepares for late-stage development.
With results from both Part A and Part B, along with upcoming regulatory discussions, Apogee plans to advance Zumilokibart into a Phase 3 trial in the second half of 2026.
APGE has traded between $26.02 and $84.56 over the past year. The stock closed Friday's trading (March 20, 2026) at $66.04, down 3.59%. In pre-market trading the stock is at $64.28, down 2.67%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.